{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T05:14:08Z","timestamp":1791695648343,"version":"4.3.4"},"reference-count":74,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2005,8]]},"DOI":"10.4065\/80.8.1087","type":"journal-article","created":{"date-parts":[[2009,1,23]],"date-time":"2009-01-23T20:26:10Z","timestamp":1232742370000},"page":"1087-1097","source":"Crossref","is-referenced-by-count":130,"title":["Non-Hodgkin Lymphoma: Diagnosis and Treatment"],"prefix":"10.4065","volume":"80","author":[{"given":"Stephen M.","family":"Ansell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Armitage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4065\/80.8.1087_bib1","series-title":"Cancer Facts & Figures 2002","author":"American Cancer Society","year":"2002"},{"key":"10.4065\/80.8.1087_bib2","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/jnci\/93.11.824","article-title":"Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends","volume":"93","author":"Howe","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.4065\/80.8.1087_bib3","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1002\/cncr.10403","article-title":"Changing incidence of non-Hodgkin lymphomas in the United States","volume":"94","author":"Clarke","year":"2002","journal-title":"Cancer"},{"key":"10.4065\/80.8.1087_bib4","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1093\/jnci\/92.15.1240","article-title":"Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995","volume":"92","author":"Groves","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"suppl 3","key":"10.4065\/80.8.1087_bib5","doi-asserted-by":"crossref","first-page":"III19","DOI":"10.1136\/gut.50.suppl_3.iii19","article-title":"Helicobacter and gastric MALT lymphoma","volume":"50","author":"Stolte","year":"2002","journal-title":"Gut"},{"key":"10.4065\/80.8.1087_bib6","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/jnci\/djh102","article-title":"Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas","volume":"96","author":"Ferreri","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.4065\/80.8.1087_bib7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMoa013376","article-title":"Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection","volume":"347","author":"Hermine","year":"2002","journal-title":"N Engl J Med"},{"key":"10.4065\/80.8.1087_bib8","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/S0140-6736(05)80084-4","article-title":"Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients","volume":"342","author":"Opelz","year":"1993","journal-title":"Lancet"},{"key":"10.4065\/80.8.1087_bib9","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/(SICI)1097-0215(19971127)73:5<645::AID-IJC6>3.0.CO;2-X","article-title":"Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden","volume":"73","author":"Cote","year":"1997","journal-title":"Int J Cancer"},{"key":"10.4065\/80.8.1087_bib10","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1200\/JCO.2004.02.104","article-title":"Utility of fine-needle aspiration as a diagnostic technique in lymphoma","volume":"22","author":"Hehn","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.4065\/80.8.1087_bib11","series-title":"World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","year":"2001"},{"key":"10.4065\/80.8.1087_bib12","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1056\/NEJM198701083160204","article-title":"Multiple recurrent genomic defects in follicular lymphoma: a possible model for cancer","volume":"316","author":"Yunis","year":"1987","journal-title":"N Engl J Med"},{"key":"10.4065\/80.8.1087_bib13","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1182\/blood.V70.2.444.444","article-title":"Intermediate- to high-grade histology of lymphomas carrying t(4;18) is associated with additional nonrandom chromosome changes","volume":"70","author":"Richardson","year":"1987","journal-title":"Blood"},{"key":"10.4065\/80.8.1087_bib14","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1182\/blood.V70.5.1554.1554","article-title":"Fifth International Workshop on Chromosomes in Leukemia-Lymphoma: correlation of chromosome abnormalities with histologic and immunologic characteristics in non-Hodgkin's lymphoma and adult T cell leukemia-lymphoma","volume":"70","year":"1987","journal-title":"Blood"},{"key":"10.4065\/80.8.1087_bib15","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/bjc.1993.144","article-title":"Beta-2 microglobulin: a prognostic factor in diffuse aggressive non-Hodgkin's lymphomas","volume":"67","author":"Johnson","year":"1993","journal-title":"Br J Cancer"},{"key":"10.4065\/80.8.1087_bib16","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1634\/theoncologist.8-5-438","article-title":"PET scans in the staging of lymphoma: current status","volume":"8","author":"Friedberg","year":"2003","journal-title":"Oncologist"},{"key":"10.4065\/80.8.1087_bib17","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1023\/A:1008394827806","article-title":"Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients","volume":"11","author":"Haioun","year":"2000","journal-title":"Ann Oncol"},{"key":"10.4065\/80.8.1087_bib18","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1182\/blood.V91.4.1178","article-title":"Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma","volume":"91","author":"van Besien","year":"1998","journal-title":"Blood"},{"key":"10.4065\/80.8.1087_bib19","first-page":"1860","article-title":"Report of the Committee on Hodgkin's Disease Staging Classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res"},{"key":"10.4065\/80.8.1087_bib20","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","author":"International Non-Hodgkin's Lymphoma Prognostic Factors Project","year":"1993","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.4065\/80.8.1087_bib21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1023\/A:1008297632358","article-title":"Is the International Prognostic Index for aggressive lymphomas useful for low-grade lymphoma patients? applicability to stage III-IV patients","volume":"8","author":"Foussard","year":"1997","journal-title":"Ann Oncol"},{"key":"10.4065\/80.8.1087_bib22","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO;2-Z","article-title":"Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors","volume":"82","author":"Bosch","year":"1998","journal-title":"Cancer"},{"key":"10.4065\/80.8.1087_bib23","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/sj.bmt.1701624","article-title":"The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma","volume":"23","author":"Moskowitz","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.4065\/80.8.1087_bib24","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1200\/JCO.1997.15.6.2296","article-title":"Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma","volume":"15","author":"Ansell","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.4065\/80.8.1087_bib25","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"10.4065\/80.8.1087_bib26","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"key":"10.4065\/80.8.1087_bib27","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nm0102-68","article-title":"Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning","volume":"8","author":"Shipp","year":"2002","journal-title":"Nat Med"},{"key":"10.4065\/80.8.1087_bib28","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"key":"10.4065\/80.8.1087_bib29","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1200\/JCO.1996.14.4.1282","article-title":"Is radiotherapy curative for stage I and II low-grade follicular lymphoma? results of a long-term follow-up study of patients treated at Stanford University","volume":"14","author":"Mac Manus","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.4065\/80.8.1087_bib30","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0167-8140(95)01600-L","article-title":"Radiotherapy results in early stage low grade nodal non-Hodgkin's lymphoma","volume":"36","author":"Pendlebury","year":"1995","journal-title":"Radiother Oncol"},{"key":"10.4065\/80.8.1087_bib31","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0360-3016(01)01747-3","article-title":"Long-term results with radiotherapy for Stage I-II follicular lymphomas","volume":"51","author":"Wilder","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.4065\/80.8.1087_bib32","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1023\/A:1008385202953","article-title":"Follicular lymphoma: have we made any progress?","volume":"11","author":"Horning","year":"2000","journal-title":"Ann Oncol"},{"key":"10.4065\/80.8.1087_bib33","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.4065\/80.8.1087_bib34","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJM198412063112303","article-title":"The natural history of initially untreated low-grade non-Hodgkin's lymphomas","volume":"311","author":"Horning","year":"1984","journal-title":"N Engl J Med"},{"key":"10.4065\/80.8.1087_bib35","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/1097-0142(197402)33:2<555::AID-CNCR2820330234>3.0.CO;2-I","article-title":"Proceedings: bi-weekly chlorambucil treatment of chronic lymphocytic leukemia","volume":"33","author":"Knospe","year":"1974","journal-title":"Cancer"},{"key":"10.4065\/80.8.1087_bib36","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1200\/JCO.1985.3.6.769","article-title":"Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma","volume":"3","author":"Ezdinli","year":"1985","journal-title":"J Clin Oncol"},{"key":"10.4065\/80.8.1087_bib37","doi-asserted-by":"crossref","first-page":"227","DOI":"10.7326\/0003-4819-76-2-227","article-title":"Advanced lymphosarcoma: intensive cyclical combination chemotherapy with cyclophosphamide, vincristine, and prednisone","volume":"76","author":"Bagley","year":"1972","journal-title":"Ann Intern Med"},{"key":"10.4065\/80.8.1087_bib38","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/1097-0142(197610)38:4<1484::AID-CNCR2820380407>3.0.CO;2-I","article-title":"Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma","volume":"38","author":"McKelvey","year":"1976","journal-title":"Cancer"},{"key":"10.4065\/80.8.1087_bib39","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.1992.10.5.790","article-title":"Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma","volume":"10","author":"Redman","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.4065\/80.8.1087_bib40","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1200\/JCO.1996.14.2.514","article-title":"Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte","volume":"14","author":"Solal-Celigny","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.4065\/80.8.1087_bib41","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/S0959-8049(98)00140-3","article-title":"Efficacy and toxicity of 2-Chlorodeoxyadenosine (Cladribine)\u20142 h infusion for 5 days\u2014as first-line treatment for advanced low grade non-Hodgkin's lymphoma","volume":"34","author":"Fridrik","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.4065\/80.8.1087_bib42","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"issue":"10, suppl 8","key":"10.4065\/80.8.1087_bib43","first-page":"63","article-title":"Newer treatments for non-Hodgkin's lymphoma: monoclonal antibodies","volume":"12","author":"Maloney","year":"1998","journal-title":"Oncology (Williston Park)"},{"issue":"5, suppl 14","key":"10.4065\/80.8.1087_bib44","first-page":"88","article-title":"CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma","volume":"26","author":"Czuczman","year":"1999","journal-title":"Semin Oncol"},{"key":"10.4065\/80.8.1087_bib45","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.4065\/80.8.1087_bib46","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","article-title":"Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma","volume":"20","author":"Hainsworth","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.4065\/80.8.1087_bib47","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1046\/j.1365-2141.2002.03535.x","article-title":"Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma","volume":"117","author":"Friedberg","year":"2002","journal-title":"Br J Haematol"},{"key":"10.4065\/80.8.1087_bib48","first-page":"2644","article-title":"Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a","volume":"6","author":"Davis","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.4065\/80.8.1087_bib49","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1182\/blood.V99.1.67","article-title":"Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma","volume":"99","author":"Ansell","year":"2002","journal-title":"Blood"},{"key":"10.4065\/80.8.1087_bib50","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1182\/blood.V96.4.1259","article-title":"Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience","volume":"96","author":"Kaminski","year":"2000","journal-title":"Blood"},{"key":"10.4065\/80.8.1087_bib51","first-page":"831a","article-title":"Final results of a randomized controlled study of the zevalin radioimmunotherapy regimen versus a standard course of rituximab immunotherapy for B-cell NHL [abstract]","volume":"96","author":"Witzig","year":"2000","journal-title":"Blood"},{"issue":"suppl 1","key":"10.4065\/80.8.1087_bib52","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0360-3016(02)03302-3","article-title":"Localized extranodal marginal zone B-cell lymphoma: clinical outcome with radiation therapy [abstract]","volume":"54","author":"Tsang","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"pt 1","key":"10.4065\/80.8.1087_bib53","first-page":"160a","article-title":"H pylori-independent MALT lymphoma of the stomach: excellent outcome with radiation alone [abstract]","volume":"11","author":"Yahalom","year":"2002","journal-title":"Blood"},{"key":"10.4065\/80.8.1087_bib54","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJM199807023390104","article-title":"Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma","volume":"339","author":"Miller","year":"1998","journal-title":"N Engl J Med"},{"issue":"pt 1","key":"10.4065\/80.8.1087_bib55","first-page":"724a","article-title":"CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin's lymphomas: update of the Southwest Oncology Group (SWOG) randomized trial [abstract]","volume":"98","author":"Miller","year":"2001","journal-title":"Blood"},{"key":"10.4065\/80.8.1087_bib56","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1200\/JCO.2004.06.088","article-title":"Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484","volume":"22","author":"Horning","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.4065\/80.8.1087_bib57","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1056\/NEJMoa042040","article-title":"ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma","volume":"352","author":"Reyes","year":"2005","journal-title":"N Engl J Med"},{"key":"10.4065\/80.8.1087_bib58","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","article-title":"Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma","volume":"328","author":"Fisher","year":"1993","journal-title":"N Engl J Med"},{"key":"10.4065\/80.8.1087_bib59","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.4065\/80.8.1087_bib60","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","article-title":"Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte","volume":"23","author":"Feugier","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.4065\/80.8.1087_bib61","first-page":"6A","article-title":"Phase III trial of rituximab-CHOP (R-CHOP) vs. CHOP with a second randomization to maintenance rituximab (MR) or observation in patients 60 years of age and older with diffuse large B-cell lymphoma (DLBCL) [abstract]","volume":"102","author":"Habermann","year":"2003","journal-title":"Blood"},{"key":"10.4065\/80.8.1087_bib62","doi-asserted-by":"crossref","first-page":"48A","DOI":"10.1182\/blood.V104.11.48.48","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood"},{"key":"10.4065\/80.8.1087_bib63","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2005.09.137","article-title":"Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia","author":"Sehn","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.4065\/80.8.1087_bib64","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.1998.16.12.3803","article-title":"Hyper-CVAD and high-dose methotrexate\/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma","volume":"16","author":"Khouri","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.4065\/80.8.1087_bib65","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"10.4065\/80.8.1087_bib66","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1200\/JCO.2001.19.11.2927","volume":"19","author":"Sweetenham","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.4065\/80.8.1087_bib67","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/annonc\/mdf253","article-title":"An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study [published correction appears in Ann Oncol. 2002;13:1961]","volume":"13","author":"Mead","year":"2002","journal-title":"Ann Oncol"},{"key":"10.4065\/80.8.1087_bib68","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1200\/JCO.2001.19.20.4014","article-title":"Brief-duration high-intensity chemotherapy for patient with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251","volume":"19","author":"Lee","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.4065\/80.8.1087_bib69","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","article-title":"High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial","volume":"21","author":"Schouten","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.4065\/80.8.1087_bib70","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"key":"10.4065\/80.8.1087_bib71","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1200\/JCO.2000.18.5.947","article-title":"Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies","volume":"18","author":"Micallef","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.4065\/80.8.1087_bib72","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/sj.bmt.1704124","article-title":"Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma","volume":"32","author":"Howe","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.4065\/80.8.1087_bib73","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1200\/JCO.1998.16.8.2817","article-title":"Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies","volume":"16","author":"Khouri","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.4065\/80.8.1087_bib74","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1200\/JCO.2002.11.088","article-title":"Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies","volume":"20","author":"Branson","year":"2002","journal-title":"J Clin Oncol"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611615942?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611615942?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T21:16:17Z","timestamp":1589490977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611615942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":74,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["S0025619611615942"],"URL":"https:\/\/doi.org\/10.4065\/80.8.1087","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2005,8]]}}}